Sorafenib inhibits the molecular components of the Raf–MEK–ERK signalling pathway, inhibiting tumour growth and VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-β, thereby inhibiting angiogenesis [159,160]. Here, KDR is linked to neoplasm.